Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Indian Journal of Thoracic and Cardiovascular Surgery
Published in: Indian Journal of Thoracic and Cardiovascular Surgery 6/2023

22-09-2023 | Aortic Valve Replacement | Critical Appraisal of Trials

Native aortic valve regurgitation: TAVR’s place in the PANTHEON

Author: Pradeep Narayan

Published in: Indian Journal of Thoracic and Cardiovascular Surgery | Issue 6/2023

Login to get access

Abstract

The PANTHEON (Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a native valve) study examined transcatheter aortic valve replacement in patients with severe pure native aortic valve regurgitation. With a real-world dataset from 16 centres in Europe and the USA, the study encompassed 201 patients. The major complications included valve embolization or migration in 12.4%, moderate to severe aortic regurgitation in 9.5% cases and need for permanent pacemaker in 22.3% cases. Self-expanding and balloon-expandable devices demonstrated similar outcomes. Those experiencing valve embolization or migration had higher 1-year adverse event rates.
Literature
1.
Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON International Project. JACC Cardiovasc Interv. 2023;16:1974–85. CrossRefPubMed
2.
VARC-3 WRITING COMMITTEE, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825–57.
3.
Vora AN, Sreenivasan J, Forrest JK. Progressing forward in transcatheter aortic valve replacement for pure aortic regurgitation. JACC Cardiovasc Interv. 2023;16:1986–9. CrossRefPubMed
4.
Jerez-Valero M, Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7:1022–32. CrossRefPubMed
5.
Daneault B, Koss E, Hahn RT, Kodali S, Williams MR, Généreux P, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2013;6:85–91. CrossRefPubMed
6.
Lasa G, Gaviria K, Sanmartín JC, Telleria M, Larman M. Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83:E112-118.
7.
Wang Y, Yu S, Qian D, Li J, Fang Z, Cheng W, et al. Anatomic predictor of severe prosthesis malposition following transcatheter aortic valve replacement with self- expandable Venus-a valve among pure aortic regurgitation: a multicenter retrospective study. Front Cardiovasc Med. 2022;9:1002071. CrossRefPubMedPubMedCentral
8.
Adam M, Tamm A, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. Transcatheter aortic valve replacement for isolated aortic regurgitation using a new self-expanding TAVR system. JACC Cardiovasc Interv. 2023;16:1965–73. CrossRefPubMed
9.
JenaValve Technology, Inc. A study to assess safety and effectiveness of the JenaValve TrilogyTM heart valve system in the treatment of high surgical risk patients with symptomatic, severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Sep [cited 2023 Sep 1]. Report No.: NCT04415047. Available from: https://​clinicaltrials.​gov/​study/​NCT04415047.
10.
JenaValve Technology, Inc. THE ALIGN-AR TRIAL: safety and effectiveness/performance of the transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation (AR) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 Sep 1]. Report No.: NCT02732704. Available from: https://​clinicaltrials.​gov/​study/​NCT02732704.
Metadata
Title
Native aortic valve regurgitation: TAVR’s place in the PANTHEON
Author
Pradeep Narayan
Publication date
22-09-2023
Publisher
Springer Nature Singapore
Published in
Indian Journal of Thoracic and Cardiovascular Surgery / Issue 6/2023
Print ISSN: 0970-9134
Electronic ISSN: 0973-7723
DOI
https://doi.org/10.1007/s12055-023-01609-1

Other articles of this Issue 6/2023

Indian Journal of Thoracic and Cardiovascular Surgery 6/2023 Go to the issue

Original Article

Simultaneous hybrid off-pump coronary artery bypass grafting and transcatheter aortic valve implantation in elderly patients

Editorial

Wire-skills for cardiac surgeons? — No, with a capital ‘N’

Invited Editorial

How should we manage complex coronary disease during transcatheter aortic valve implantation?

Case report

Trans-aortic DORV repair

Correspondence

AI-generated potential research paper: overview in cardiac surgery—Is this the future?

Images

Thoracic lipoblastoma in a 7-month-old infant